PAVmed Stock Forecast, Price & News

-1.03 (-17.82 %)
(As of 04/13/2021 03:59 PM ET)
Today's Range
Now: $4.75
50-Day Range
MA: $4.54
52-Week Range
Now: $4.75
Volume199,875 shs
Average Volume4.73 million shs
Market Capitalization$391.69 million
P/E RatioN/A
Dividend YieldN/A
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.
PAVmed logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:PAVM
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value($0.18) per share


Net Income$-16,460,000.00


Market Cap$391.69 million
Next Earnings Date5/20/2021 (Estimated)
OptionableNot Optionable


PAVmed (NASDAQ:PAVM) Shares Gap Down to $6.24
April 7, 2021 |
PAVmed (NASDAQ:PAVM) Reaches New 1-Year High at $6.52
April 6, 2021 |
Major Indexes Are Down, but Market's Up in the Air - RealMoney
March 30, 2021 |
Form 8-K PAVmed Inc. For: Mar 02 -
March 3, 2021 |
PAVmed Retires Convertible Debt - Yahoo Finance
March 3, 2021 |
PAVmed Retires Convertible Debt
March 3, 2021 |
See More Headlines


Overall MarketRank

1.39 out of 5 stars

Medical Sector

920th out of 2,016 stocks

Surgical & Medical Instruments Industry

90th out of 169 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
-1.03 (-17.82 %)
(As of 04/13/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PAVM News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

PAVmed (NASDAQ:PAVM) Frequently Asked Questions

Is PAVmed a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PAVmed stock.
View analyst ratings for PAVmed
or view top-rated stocks.

What stocks does MarketBeat like better than PAVmed?

Wall Street analysts have given PAVmed a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PAVmed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is PAVmed's next earnings date?

PAVmed is scheduled to release its next quarterly earnings announcement on Thursday, May 20th 2021.
View our earnings forecast for PAVmed

How were PAVmed's earnings last quarter?

PAVmed Inc. (NASDAQ:PAVM) released its quarterly earnings results on Sunday, February, 21st. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.06.
View PAVmed's earnings history

How has PAVmed's stock been impacted by COVID-19 (Coronavirus)?

PAVmed's stock was trading at $1.74 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PAVM stock has increased by 181.0% and is now trading at $4.89.
View which stocks have been most impacted by COVID-19

What guidance has PAVmed issued on next quarter's earnings?

PAVmed updated its fourth quarter 2020 Pre-Market earnings guidance on Monday, February, 22nd. The company provided earnings per share (EPS) guidance of -0.12--0.12 for the period, compared to the Thomson Reuters consensus EPS estimate of $-0.11.

What price target have analysts set for PAVM?

4 Wall Street analysts have issued 1-year target prices for PAVmed's stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate PAVmed's share price to reach $6.75 in the next year. This suggests a possible upside of 38.0% from the stock's current price.
View analysts' price targets for PAVmed
or view top-rated stocks among Wall Street analysts.

Who are PAVmed's key executives?

PAVmed's management team includes the following people:
  • Dr. Lishan Aklog M.D., Chairman & CEO (Age 55, Pay $686.3k)
  • Mr. Dennis M. McGrath CPA, Pres, CFO & Corp. Sec. (Age 64, Pay $345.2k)
  • Dr. Brian J. deGuzman M.D., Chief Medical Officer & Exec. VP of Clinical Affairs (Age 56, Pay $305.2k)
  • Mike Havrilla, Director of Investor Relations
  • Mr. Shaun M. O'Neil, Chief Commercial Officer

Who are some of PAVmed's key competitors?

What other stocks do shareholders of PAVmed own?

What is PAVmed's stock symbol?

PAVmed trades on the NASDAQ under the ticker symbol "PAVM."

Who are PAVmed's major shareholders?

PAVmed's stock is owned by many different retail and institutional investors. Top institutional investors include Valeo Financial Advisors LLC (0.35%). Company insiders that own PAVmed stock include Dennis M Mcgrath, Lishan Aklog and Matthew Sirovich.
View institutional ownership trends for PAVmed

Which major investors are selling PAVmed stock?

PAVM stock was sold by a variety of institutional investors in the last quarter, including Valeo Financial Advisors LLC.
View insider buying and selling activity for PAVmed
or view top insider-selling stocks.

How do I buy shares of PAVmed?

Shares of PAVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PAVmed's stock price today?

One share of PAVM stock can currently be purchased for approximately $4.89.

How much money does PAVmed make?

PAVmed has a market capitalization of $403.23 million.

How many employees does PAVmed have?

PAVmed employs 25 workers across the globe.

What is PAVmed's official website?

The official website for PAVmed is

Where are PAVmed's headquarters?

PAVmed is headquartered at ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165.

How can I contact PAVmed?

PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company can be reached via phone at 212-949-4319 or via email at [email protected]

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.